| | | | | | | | | | |
|
|
| Dockets Entered
On November 15, 2005
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1986V-0194
|
| Rainbow Hene Serial #3050
|
|
|
| 1995N-0205
|
| OTC Bronchodilator Drug Products
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
| 1999N-4282
|
| Biotechnology in the Year 2000 and Beyond; Public Meetings
|
|
|
| 1999P-1340
|
| Declared Eternity eau de Parfum Misbranded
|
|
|
| 2000P-1211
|
| Establish Mandatory Pre-Market Safety Testing for GE Foods
|
|
|
| 2002M-0118
|
| Disintegrator Insulin Needle Destruction Device, P010040
|
|
|
| 2002N-0273
|
| Animal Proteins Prohibited in Ruminant Feed
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
| 2003V-0428
|
| Laser Light Show
|
|
|
| 2004N-0461
|
| Amendment to 25.34; Categorical Exclusions Environmental Assessment
|
|
|
| 2004P-0457
|
| Reclassifcation of the Buechel-Pappas Unconstrained Ankle Prosthesis
|
|
|
| 2005A-0131
|
| Request for an Advisory Opinion concerning a 510(k) for a medical or dental device
|
|
|
| 2005D-0348
|
| Guidance for Industry and Food and Drug Administration: Procedures for Handling Post-Approval Studies Imposed by PMA Order
|
|
|
| 2005D-0401
|
| Guidance for Industry and FDA Staff: Compliance with Section 301 of the Medical Device User Fee and Modernization Act of 2002, as amended Prominent and Conspicuous Mark of Manufacturers on Single-Us
|
|
|
|
|
|
| 2005M-0270
|
| P030049 - ADVIA Centaur HBsAg ReadyPack Reagents, ADVIA Centaur HBsAg Confirmatory ReadyPack Reagents, and ADVIA Centaur HBsAg Quality Control Material - Approved 5/31/05
|
|
|
| 2005N-0317
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Record Retention Requirements for the Soy Protein and Risk of Coronary Heart Disease Health Claim
|
|
|
| 2005N-0345
|
| Drug Approvals: Circumstances under which an active ingredient may be simultaneously marketed in both a prescription drug product and an over-the-counter drug product
|
|
|
| 2005N-0424
|
| Agency Information Collection Activities; Announcement of OMB Approval; Survey on Program Funding
|
|
|
| 2005P-0213
|
| To change the classification of EEG electrodes currently classified as class II and requiring 510K approvals\
|
|
|
| 2005P-0257
|
| Methylphenidate Hydrochloride Extended Release Tablets, 72 mg, is suitable for submission as an ANDA
|
|
|
| 2005P-0267
|
| Remove from label for propofol (Diprivan) the warning that propofol should be administered only by trained persons
|
|
|
| 2005P-0352
|
| bioequivalence criteria be applied separately to oxybutynin and its active metabolite, desethyloxbutynin
|
|
|
| 2005P-0384
|
| Deficient Peripheral Metabolism of Thyroxine to Triiodothyronine
|
|
|
| 2005P-0405
|
| Reclassification for Metal/Metal Semiconstrained Hip Joint Prostheses with Cemented or Uncemented Acetabular Components
|
|
|
| 2005P-0433
|
| Adoption of Harmonization Policy by the U.S. Codex Delegation and US Policy in harmony with DSHEA and 19 U.S.C. 3512
|
|
|
| 2005P-0459
|
| To enforce ban on carbon monoxide gas in fresh meat packaging
|
|
|
| 2005P-0460
|
| Determination of Ramipril Tablets, 1.25 mg, 2.5 mg, 5 mg and 10 mg
|
|
|
| 2005P-0462
|
| Initiate a Transfer of Regulatory and Classification Responsibilities over Mercury Amalgam
|
|
|
| 2005P-0464
|
| To move metered-dose inhalers (MDI) containing the single active moieties beclomethasone, fluticasone, and salmeterol, respectively, from the essential-use list of ozone-depleting substance
|
|
|
| 1986V-0194
|
| Rainbow Hene Serial #3050
|
|
|
| VRA
15
|
| HFZ-200 to Lasertainment Productions International
|
| Vol #:
|
| 1
|
|
|
| 1995N-0205
|
| OTC Bronchodilator Drug Products
|
|
|
| EMC 2
|
| Allergy & Asthma Network Mothers of Asthmatics
|
| Vol #:
|
| 7
|
|
| | | | | | | | |
|
|
| EMC 618
|
| T. Rafferty
|
| Vol #:
|
| 24
|
|
|
| 2000P-1211
|
| Establish Mandatory Pre-Market Safety Testing for GE Foods
|
|
|
| EMC 5852
|
| D. Shelton
|
| Vol #:
|
| 789
|
|
|
| EMC 5853
|
| L. Lo
|
| Vol #:
|
| 789
|
|
|
| 2002M-0118
|
| Disintegrator Insulin Needle Destruction Device, P010040
|
|
|
| C
1
|
| Safeguard Medical Technologies, LLC
|
| Vol #:
|
| 1
|
|
|
| 2002N-0273
|
| Animal Proteins Prohibited in Ruminant Feed
|
|
|
| C 57
|
| R. Hunt
|
| Vol #:
|
| 4
|
|
|
| C 58
|
| B. Callahan
|
| Vol #:
|
| 4
|
|
|
| EMC 122
|
| F. Hajcak
|
| Vol #:
|
| 14
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
| EMC 1153
|
| J. Wheetley
|
| Vol #:
|
| 11
|
|
|
| EMC 1154
|
| S. Ahonen
|
| Vol #:
|
| 11
|
|
|
| EMC 1155
|
| M. Oliver
|
| Vol #:
|
| 11
|
|
|
| EMC 1156
|
| M. Oliver
|
| Vol #:
|
| 11
|
|
|
| EMC 1157
|
| S. Heath
|
| Vol #:
|
| 11
|
|
|
| 2003V-0428
|
| Laser Light Show
|
|
|
| VRA
2
|
| HFZ-200 to Cunningham Production Resources
|
| Vol #:
|
| 1
|
|
|
| 2004N-0461
|
| Amendment to 25.34; Categorical Exclusions Environmental Assessment
|
|
|
| NFR
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2004P-0457
|
| Reclassifcation of the Buechel-Pappas Unconstrained Ankle Prosthesis
|
|
|
| SUP
2
|
| Endotec, Incorporated
|
| Vol #:
|
| 2
|
|
|
| 2005A-0131
|
| Request for an Advisory Opinion concerning a 510(k) for a medical or dental device
|
|
|
| WDL
1
|
| Great Lakes Orthodontics, Ltd.
|
| Vol #:
|
| 1
|
|
|
| 2005D-0348
|
| Guidance for Industry and Food and Drug Administration: Procedures for Handling Post-Approval Studies Imposed by PMA Order
|
|
|
| C
1
|
| Cook Group, Inc. (Cook)
|
| Vol #:
|
| 1
|
|
|
| 2005D-0401
|
| Guidance for Industry and FDA Staff: Compliance with Section 301 of the Medical Device User Fee and Modernization Act of 2002, as amended Prominent and Conspicuous Mark of Manufacturers on Single-Us
|
|
|
|
|
|
|
| C
2
|
| Alliance Medical Corporation
|
| Vol #:
|
| 1
|
|
|
| 2005M-0270
|
| P030049 - ADVIA Centaur HBsAg ReadyPack Reagents, ADVIA Centaur HBsAg Confirmatory ReadyPack Reagents, and ADVIA Centaur HBsAg Quality Control Material - Approved 5/31/05
|
|
|
|
|
|
| | | | | | | | |
|
|
| C
1
|
| Florida Blood Services
|
| Vol #:
|
| 1
|
|
|
| 2005N-0317
|
| Agency Information Collection Activities; Proposed Collection; Comment Request; Record Retention Requirements for the Soy Protein and Risk of Coronary Heart Disease Health Claim
|
|
|
|
|
|
| N
2
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2005N-0345
|
| Drug Approvals: Circumstances under which an active ingredient may be simultaneously marketed in both a prescription drug product and an over-the-counter drug product
|
|
|
| C 487
|
| K. Raviele, M.D., F.A.C.O.G.
|
| Vol #:
|
| 165
|
|
|
| 2005N-0424
|
| Agency Information Collection Activities; Announcement of OMB Approval; Survey on Program Funding
|
|
|
| NAL
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| SS
1
|
| Supporting Statement
|
| Vol #:
|
| 1
|
|
|
| 2005P-0213
|
| To change the classification of EEG electrodes currently classified as class II and requiring 510K approvals\
|
|
|
| LET
1
|
| HFZ-001 to Scientific Laboratory Products LTD
|
| Vol #:
|
| 1
|
|
|
| 2005P-0257
|
| Methylphenidate Hydrochloride Extended Release Tablets, 72 mg, is suitable for submission as an ANDA
|
|
|
| PAV
1
|
| HFD-600 to The Weinberg Group Inc.
|
| Vol #:
|
| 1
|
|
|
| 2005P-0267
|
| Remove from label for propofol (Diprivan) the warning that propofol should be administered only by trained persons
|
|
|
| C
75
|
| American Association of Nurse Anesthetists (AANA)
|
| Vol #:
|
| 20
|
|
|
| 2005P-0352
|
| bioequivalence criteria be applied separately to oxybutynin and its active metabolite, desethyloxbutynin
|
|
|
| C
2
|
| Mylan Pharmaceuticals, Inc.
|
| Vol #:
|
| 2
|
|
|
| 2005P-0384
|
| Deficient Peripheral Metabolism of Thyroxine to Triiodothyronine
|
|
|
| C 1
|
| C. Reeder
|
| Vol #:
|
| 1
|
|
|
| 2005P-0405
|
| Reclassification for Metal/Metal Semiconstrained Hip Joint Prostheses with Cemented or Uncemented Acetabular Components
|
|
|
| LET
1
|
| Orthopedic Surgical Manufacturers Association (OSMA)
|
| Vol #:
|
| 4
|
|
|
| 2005P-0433
|
| Adoption of Harmonization Policy by the U.S. Codex Delegation and US Policy in harmony with DSHEA and 19 U.S.C. 3512
|
|
|
| C 1
|
| J. Stuart
|
| Vol #:
|
| 1
|
|
|
| 2005P-0459
|
| To enforce ban on carbon monoxide gas in fresh meat packaging
|
|
|
| ACK
1
|
| HFA-305 to Kalsec Inc.
|
| Vol #:
|
| 1
|
|
|
| CP
1
|
| Kalsec Inc.
|
| Vol #:
|
| 1
|
|
|
| 2005P-0460
|
| Determination of Ramipril Tablets, 1.25 mg, 2.5 mg, 5 mg and 10 mg
|
|
|
| ACK
1
|
| HFA-305 to Lachman Consultant Services, Inc.
|
| Vol #:
|
| 1
|
|
|
| CP
1
|
| Lachman Consultant Services, Inc.
|
| Vol #:
|
| 1
|
|
|
| 2005P-0462
|
| Initiate a Transfer of Regulatory and Classification Responsibilities over Mercury Amalgam
|
|